Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy.
A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1b CLINICAL STUDY OF CMP 001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA
- ClinicalTrials.gov Identifier: NCT02680184
- Protocol Number: 16-377
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required